Congratulations to the team at NeuBase for being listed on the Russell 3000R index. Bear Creek Capital is proud to have been associated with your great leadership team. We not only believe in your mission, but we believe in the quality of the people you have assembled to lead you forward.
NeuBase Therapeutics, Inc., is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.”
Huh, you ask? What that means in simpler terms is that their proprietary platform allows them to develop “targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures.”
